The Synthetic Tellurium Compound, AS101, Is a Novel Inhibitor of IL-1 β Converting Enzyme
The organotellurium compound, trichloro(dioxoethylene-O,O') tellurate (AS101) has been shown previously to exert diverse biologic activities both in vitro and in vivo. This compound was recently found to react with thiols and to catalyze their oxidation. This property of AS101 raises the possib...
Gespeichert in:
Veröffentlicht in: | Journal of interferon & cytokine research 2007-06, Vol.27 (6), p.453-462 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 462 |
---|---|
container_issue | 6 |
container_start_page | 453 |
container_title | Journal of interferon & cytokine research |
container_volume | 27 |
creator | Brodsky, Miri Yosef, Sigal Galit, Rushkin Albeck, Michael Longo, Dan L. Albeck, Amnon Sredni, Benjamin |
description | The organotellurium compound, trichloro(dioxoethylene-O,O') tellurate (AS101) has been shown previously to exert diverse biologic activities both in vitro and in vivo. This compound was recently found to react with thiols and to catalyze their oxidation. This property of AS101 raises the possibility that it may serve as a cysteine protease inhibitor. In the present study, using a substrate-specific enzymatic assay, we show that treatment of caspase-1 (interleukin-1 beta [IL-1 beta ] converting enzyme [ICE]) with AS101 inhibits its enzymatic activity in a dose-dependent manner. Moreover, the results show that AS101 treatment causes a significant reduction in the active form of IL-18 and EL-1 beta in peripheral blood mononuclear cells (PBMC) and in human HaCat keratinocytes. We further demonstrate that the inhibitory effect of AS101 does not involve nitric oxide (NO) or interferon- gamma (IFN- gamma ), two possible regulators of IL-18 production, and does not occur at the mRNA level, suggesting a posttranscriptional mechanism of action. More importantly, AS101 downregulates EL-18 and IL-1 beta serum levels in a mouse model of lipopolysaccharide (LPS)-induced sepsis, resulting in increased survival. Recent studies emphasize the pathophysiologic role of IL-18 and IL-1 beta in a variety of inflammatory diseases. Thus, their blockage by the nontoxic compound, AS101, currently used in clinical studies, may provide clinical advantage in the treatment of these diseases. |
doi_str_mv | 10.1089/jir.2007.0168 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20294865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20294865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c268t-3a2040bbb324d8f5e5fdd53999245063d9e159f8e3528012f173db3a990b73803</originalsourceid><addsrcrecordid>eNotkL1OwzAcxC0EEqUwsntiqsvfdpzYY1UViFTB0LKwWPlwqKskLnZSKTwWD8IzkapMd8PdSfdD6J7CnIJUj3vr5wwgmQON5QWaUCESkkSxuBw9JIooBck1uglhDwCxZGqCPrY7gzdD2-1MZwu8NXXde9s3eOmag-vbcoYXGwp0htOAM_zqjqbGabuzue2cx67C6ZpQ_PszFtqj8Z1tP_Gq_R4ac4uuqqwO5u5fp-j9abVdvpD123O6XKxJwWLZEZ4xiCDPc86iUlbCiKosBVdKsUhAzEtlqFCVNFwwCZRVNOFlzrPxTJ5wCXyKHs67B---ehM63dhQjEey1rg-aAZMRTIWY5Ccg4V3IXhT6YO3TeYHTUGfCOqRoD4R1CeC_A_XY2JO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20294865</pqid></control><display><type>article</type><title>The Synthetic Tellurium Compound, AS101, Is a Novel Inhibitor of IL-1 β Converting Enzyme</title><source>Alma/SFX Local Collection</source><creator>Brodsky, Miri ; Yosef, Sigal ; Galit, Rushkin ; Albeck, Michael ; Longo, Dan L. ; Albeck, Amnon ; Sredni, Benjamin</creator><creatorcontrib>Brodsky, Miri ; Yosef, Sigal ; Galit, Rushkin ; Albeck, Michael ; Longo, Dan L. ; Albeck, Amnon ; Sredni, Benjamin</creatorcontrib><description>The organotellurium compound, trichloro(dioxoethylene-O,O') tellurate (AS101) has been shown previously to exert diverse biologic activities both in vitro and in vivo. This compound was recently found to react with thiols and to catalyze their oxidation. This property of AS101 raises the possibility that it may serve as a cysteine protease inhibitor. In the present study, using a substrate-specific enzymatic assay, we show that treatment of caspase-1 (interleukin-1 beta [IL-1 beta ] converting enzyme [ICE]) with AS101 inhibits its enzymatic activity in a dose-dependent manner. Moreover, the results show that AS101 treatment causes a significant reduction in the active form of IL-18 and EL-1 beta in peripheral blood mononuclear cells (PBMC) and in human HaCat keratinocytes. We further demonstrate that the inhibitory effect of AS101 does not involve nitric oxide (NO) or interferon- gamma (IFN- gamma ), two possible regulators of IL-18 production, and does not occur at the mRNA level, suggesting a posttranscriptional mechanism of action. More importantly, AS101 downregulates EL-18 and IL-1 beta serum levels in a mouse model of lipopolysaccharide (LPS)-induced sepsis, resulting in increased survival. Recent studies emphasize the pathophysiologic role of IL-18 and IL-1 beta in a variety of inflammatory diseases. Thus, their blockage by the nontoxic compound, AS101, currently used in clinical studies, may provide clinical advantage in the treatment of these diseases.</description><identifier>ISSN: 1079-9907</identifier><identifier>EISSN: 1557-7465</identifier><identifier>DOI: 10.1089/jir.2007.0168</identifier><language>eng</language><ispartof>Journal of interferon & cytokine research, 2007-06, Vol.27 (6), p.453-462</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c268t-3a2040bbb324d8f5e5fdd53999245063d9e159f8e3528012f173db3a990b73803</citedby><cites>FETCH-LOGICAL-c268t-3a2040bbb324d8f5e5fdd53999245063d9e159f8e3528012f173db3a990b73803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Brodsky, Miri</creatorcontrib><creatorcontrib>Yosef, Sigal</creatorcontrib><creatorcontrib>Galit, Rushkin</creatorcontrib><creatorcontrib>Albeck, Michael</creatorcontrib><creatorcontrib>Longo, Dan L.</creatorcontrib><creatorcontrib>Albeck, Amnon</creatorcontrib><creatorcontrib>Sredni, Benjamin</creatorcontrib><title>The Synthetic Tellurium Compound, AS101, Is a Novel Inhibitor of IL-1 β Converting Enzyme</title><title>Journal of interferon & cytokine research</title><description>The organotellurium compound, trichloro(dioxoethylene-O,O') tellurate (AS101) has been shown previously to exert diverse biologic activities both in vitro and in vivo. This compound was recently found to react with thiols and to catalyze their oxidation. This property of AS101 raises the possibility that it may serve as a cysteine protease inhibitor. In the present study, using a substrate-specific enzymatic assay, we show that treatment of caspase-1 (interleukin-1 beta [IL-1 beta ] converting enzyme [ICE]) with AS101 inhibits its enzymatic activity in a dose-dependent manner. Moreover, the results show that AS101 treatment causes a significant reduction in the active form of IL-18 and EL-1 beta in peripheral blood mononuclear cells (PBMC) and in human HaCat keratinocytes. We further demonstrate that the inhibitory effect of AS101 does not involve nitric oxide (NO) or interferon- gamma (IFN- gamma ), two possible regulators of IL-18 production, and does not occur at the mRNA level, suggesting a posttranscriptional mechanism of action. More importantly, AS101 downregulates EL-18 and IL-1 beta serum levels in a mouse model of lipopolysaccharide (LPS)-induced sepsis, resulting in increased survival. Recent studies emphasize the pathophysiologic role of IL-18 and IL-1 beta in a variety of inflammatory diseases. Thus, their blockage by the nontoxic compound, AS101, currently used in clinical studies, may provide clinical advantage in the treatment of these diseases.</description><issn>1079-9907</issn><issn>1557-7465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNotkL1OwzAcxC0EEqUwsntiqsvfdpzYY1UViFTB0LKwWPlwqKskLnZSKTwWD8IzkapMd8PdSfdD6J7CnIJUj3vr5wwgmQON5QWaUCESkkSxuBw9JIooBck1uglhDwCxZGqCPrY7gzdD2-1MZwu8NXXde9s3eOmag-vbcoYXGwp0htOAM_zqjqbGabuzue2cx67C6ZpQ_PszFtqj8Z1tP_Gq_R4ac4uuqqwO5u5fp-j9abVdvpD123O6XKxJwWLZEZ4xiCDPc86iUlbCiKosBVdKsUhAzEtlqFCVNFwwCZRVNOFlzrPxTJ5wCXyKHs67B---ehM63dhQjEey1rg-aAZMRTIWY5Ccg4V3IXhT6YO3TeYHTUGfCOqRoD4R1CeC_A_XY2JO</recordid><startdate>200706</startdate><enddate>200706</enddate><creator>Brodsky, Miri</creator><creator>Yosef, Sigal</creator><creator>Galit, Rushkin</creator><creator>Albeck, Michael</creator><creator>Longo, Dan L.</creator><creator>Albeck, Amnon</creator><creator>Sredni, Benjamin</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>200706</creationdate><title>The Synthetic Tellurium Compound, AS101, Is a Novel Inhibitor of IL-1 β Converting Enzyme</title><author>Brodsky, Miri ; Yosef, Sigal ; Galit, Rushkin ; Albeck, Michael ; Longo, Dan L. ; Albeck, Amnon ; Sredni, Benjamin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c268t-3a2040bbb324d8f5e5fdd53999245063d9e159f8e3528012f173db3a990b73803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brodsky, Miri</creatorcontrib><creatorcontrib>Yosef, Sigal</creatorcontrib><creatorcontrib>Galit, Rushkin</creatorcontrib><creatorcontrib>Albeck, Michael</creatorcontrib><creatorcontrib>Longo, Dan L.</creatorcontrib><creatorcontrib>Albeck, Amnon</creatorcontrib><creatorcontrib>Sredni, Benjamin</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of interferon & cytokine research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brodsky, Miri</au><au>Yosef, Sigal</au><au>Galit, Rushkin</au><au>Albeck, Michael</au><au>Longo, Dan L.</au><au>Albeck, Amnon</au><au>Sredni, Benjamin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Synthetic Tellurium Compound, AS101, Is a Novel Inhibitor of IL-1 β Converting Enzyme</atitle><jtitle>Journal of interferon & cytokine research</jtitle><date>2007-06</date><risdate>2007</risdate><volume>27</volume><issue>6</issue><spage>453</spage><epage>462</epage><pages>453-462</pages><issn>1079-9907</issn><eissn>1557-7465</eissn><abstract>The organotellurium compound, trichloro(dioxoethylene-O,O') tellurate (AS101) has been shown previously to exert diverse biologic activities both in vitro and in vivo. This compound was recently found to react with thiols and to catalyze their oxidation. This property of AS101 raises the possibility that it may serve as a cysteine protease inhibitor. In the present study, using a substrate-specific enzymatic assay, we show that treatment of caspase-1 (interleukin-1 beta [IL-1 beta ] converting enzyme [ICE]) with AS101 inhibits its enzymatic activity in a dose-dependent manner. Moreover, the results show that AS101 treatment causes a significant reduction in the active form of IL-18 and EL-1 beta in peripheral blood mononuclear cells (PBMC) and in human HaCat keratinocytes. We further demonstrate that the inhibitory effect of AS101 does not involve nitric oxide (NO) or interferon- gamma (IFN- gamma ), two possible regulators of IL-18 production, and does not occur at the mRNA level, suggesting a posttranscriptional mechanism of action. More importantly, AS101 downregulates EL-18 and IL-1 beta serum levels in a mouse model of lipopolysaccharide (LPS)-induced sepsis, resulting in increased survival. Recent studies emphasize the pathophysiologic role of IL-18 and IL-1 beta in a variety of inflammatory diseases. Thus, their blockage by the nontoxic compound, AS101, currently used in clinical studies, may provide clinical advantage in the treatment of these diseases.</abstract><doi>10.1089/jir.2007.0168</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1079-9907 |
ispartof | Journal of interferon & cytokine research, 2007-06, Vol.27 (6), p.453-462 |
issn | 1079-9907 1557-7465 |
language | eng |
recordid | cdi_proquest_miscellaneous_20294865 |
source | Alma/SFX Local Collection |
title | The Synthetic Tellurium Compound, AS101, Is a Novel Inhibitor of IL-1 β Converting Enzyme |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A29%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Synthetic%20Tellurium%20Compound,%20AS101,%20Is%20a%20Novel%20Inhibitor%20of%20IL-1%20%CE%B2%20Converting%20Enzyme&rft.jtitle=Journal%20of%20interferon%20&%20cytokine%20research&rft.au=Brodsky,%20Miri&rft.date=2007-06&rft.volume=27&rft.issue=6&rft.spage=453&rft.epage=462&rft.pages=453-462&rft.issn=1079-9907&rft.eissn=1557-7465&rft_id=info:doi/10.1089/jir.2007.0168&rft_dat=%3Cproquest_cross%3E20294865%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20294865&rft_id=info:pmid/&rfr_iscdi=true |